Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 19/20 | 0.76 |
| ▸ | CRBN | Q96SW2 | 19/20 | 0.76 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.54 |
| ▸ | TNF | P01375 | 1/20 | 0.54 |
| ▸ | IL1B | P01584 | 1/20 | 0.54 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.54 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12250734 | 1.00 | DDB1 (0.76) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL501914 | 1.00 | DDB1 (0.76) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL12250744 | 1.00 | DDB1 (0.76) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL2384231 | 0.92 | DDB1 (0.71) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL21227737 | 0.91 | DDB1 (0.77) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL2381226 | 0.90 | CRBN (0.67) | DDB1CRBN | |
| SCHEMBL21071278 | 0.89 | CRBN (0.74) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL5545253 | 0.88 | DDB1 (0.77) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL23842551 | 0.88 | CRBN (0.72) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL30805459 | 0.88 | CRBN (0.72) | DDB1CRBNIKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-4611798-A1 | METHODS OF TREATMENT WITH T CELL THERAPY AND IMMUNOMODULATORY AGENT MAINTENANCE THERAPY | CELGENE CORPORATION (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| CN-119546638-A | Therapeutic methods for two-line therapy of CD19 targeted CAR T cells | 朱诺治疗学股份有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-118948892-A | Combination of cell therapy with immunomodulatory compounds | 朱诺治疗学股份有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118662614-A | Articles and methods of treatment using adoptive cell therapy | 朱诺治疗学股份有限公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-110290807-B | Methods of determining CAR-T cell dosing | 朱诺治疗学股份有限公司 | 2024-06-14 | — | — | CN | disclosed |
| WO-2024097905-A1 | METHODS OF TREATMENT WITH T CELL THERAPY AND IMMUNOMODULATORY AGENT MAINTENANCE THERAPY | CELGENE CORPORATION (US) | 2024-05-10 | — | — | WO | disclosed |
| CN-111225675-B | Articles and methods of treatment using adoptive cell therapy | 朱诺治疗学股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-115282165-A | Natural killer cells from placenta | 细胞结构公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-115137753-A | Natural killer cells from placenta | 细胞结构公司 | 2022-10-04 | — | — | CN | disclosed |